Research has found that artificial intelligence in drug discovery will be worth $1,434 million by the end of 2024.
List view / Grid view
Filter the results
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
The CyBio FeliX pipetting system was used to perform all liquid handling steps of the library preparation workflow for personal genome analysis.
A novel computational method has led to the discovery of genes whose alteration may contribute to cancer susceptibility and may lead to new therapeutic targets for cancers.
Researchers in Australia and the US have launched the first open-source database detailing genetic variants that impact human health and disease.
New software has been developed that can reveal the detailed RNA-binding properties of proteins, which is important for characterising the pathology of many diseases.
A machine-learning algorithm has been created that automates high-throughput screens of epigenetic medicines.
A drug discovery platform for mental health treatment could also help to identify mechanisms for the treatment of substance use disorders.
Researchers have developed CRISPR-Cas13 enzyme-based technology that can be programmed to both detect and destroy RNA-based viruses in human cells.
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
New protein-painting technology could lead to developing cancer immunotherapy medicines that can be administered as a pill.
A new study has shown that it is possible to specifically conduct the fate of tissue cells by using visible light.
Researchers have used whole genome sequencing to analyse breast cancers and reveal which are more responsive to treatments, which could improve the development of oncologic therapies.
A new platform brings together genome editing with magnetic cell sorting to reveal new drug targets for cancer and regenerative medicine.
A new platform combines AI, flow chemistry and robotics to minimise the need for human intervention in the synthesis process.